<DOC>
	<DOCNO>NCT01646814</DOCNO>
	<brief_summary>This trial Phase 2 , randomize , control study compare degree mucosal injury oral administration investigational product , PL2200 , market 325 mg immediate-release aspirin product . Each group treat either immediate-release aspirin tablet PL2200 capsule 325 mg per day 6 week , evaluate via endoscope gastrointestinal injury may cause study medication .</brief_summary>
	<brief_title>Evaluation Upper GI Ulceration Induced PL2200 Versus Aspirin At-Risk Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Healthy volunteer , ≥50 ≤75 year age . No endoscopically observe baseline gastrointestinal lesion . Baseline gastrointestinal lesion abnormal screening/baseline laboratory parameter deem clinically significant Investigator . Significant history substance abuse uncontrolled acute chronic medical illness . Active H. pylori infection . Current use lowdose aspirin cardioprevention , ulcerogenic medication , gastroprotective , antiplatelet agent . Hypersensitivity aspirin NSAIDs .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>comparison incidence</keyword>
	<keyword>treatment group .</keyword>
</DOC>